Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma after experimental treatment with CAN-2409 Estimated overall.
Candel Therapeutics (CADL) Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation.
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.